DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk clinically localised prostate cancer | NYU Langone Health

Go Back to All Clinical Trials

DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk clinically localised prostate cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Prostate Cancer
Age: Between 18 years - 100 years
Gender: Male

Other Inclusion Criteria:

1) Pathological diagnosis of adenocarcinoma of the prostate with a very high risk of recurrence and EITHER planned for primary radiation or salvage radiation therapy after radical prostatectomy. 2) Willing to complete health-related quality of life (HRQL) questionnaires UNLESS is unable to complete because of literacy or limited vision.

You may not be eligible for this study if the following are true:

1) Prostate cancer with predominant non-adenocarcinoma features (sarcomatoid or spindle cell or neuroendocrine small cell or squamous cell components or other non-adenocarcinoma). 2) Involvement of LNs by conventional CT imaging superior to the common iliac artery bifurcation, and/or outside the pelvis. 3) Evidence of metastatic disease.